Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 6NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 5Leukemia, Myeloid, Acute 3Rectal Neoplasms 2Prostatic Neoplasms 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Diseases 2Congenital Abnormalities 2Colonic Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Anemia, Refractory 2Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytopenia 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sepsis 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1

Interventions

Imatinib Mesylate 10Cytarabine 7Cyclosporine 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Dasatinib 4Tacrolimus 3Interferon-alpha 3Idarubicin 3Hydroxyurea 3Busulfan 3tipifarnib 2fludarabine 2belinostat 2Radiotherapy 2Mycophenolic Acid 2Ipilimumab 2Homoharringtonine 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Decitabine 2CTLA-4 Antigen 2Bortezomib 2veliparib 1temsirolimus 1tanespimycin 1sargramostim 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT00488592 2021-07-12

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 7 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡